New cholesterol guideline could mean 1 in 2 US adults eligible for statins

Clinical Takeaway: Expect more patients, especially younger adults and those with elevated lifetime risk, to qualify for statins under the 2026 guideline. Coronary artery calcium scoring and risk-enhancing factors may play a larger role in treatment decisions for borderline-risk patients.

The new guideline shifts prevention toward earlier and more personalized treatment, potentially affecting tens of millions of adults and increasing the importance of long-term cardiovascular risk assessment.

Three studies published in JAMA examined the population-level impact of the 2026 ACC/AHA multisociety dyslipidemia guideline and found that its combination of new PREVENT risk equations, expanded age range, lower risk thresholds, and incorporation of long-term risk substantially broadens eligibility for preventive lipid-lowering therapy.

Using nationally representative NHANES data, investigators estimated that 87.5 million U.S. adults aged 30 to 79 years, or 56.6% of the target population, now meet criteria for primary-prevention statin therapy. About 21.5 million adults become newly eligible under the updated recommendations, with eligibility exceeding 90% among adults aged 70 to 79 years. Newly eligible individuals generally had lower short-term risk, averaging about a 3% 10-year ASCVD risk.

A separate analysis found that the switch from pooled cohort equations to PREVENT reclassified roughly 22% of adults, with about two-thirds moving to lower-risk categories and one-third moving higher. Despite this reshuffling, the overall proportion recommended for lipid-lowering therapy changed little, highlighting a shift toward more individualized risk assessment rather than less treatment.

Meanwhile, LDL-C goal attainment remains a major challenge. Approximately one-third of primary-prevention adults and about 80% of those with established ASCVD have LDL-C levels above the new guideline targets. Among those above goal, 76.1% in primary prevention and 37.6% in secondary prevention reported receiving no lipid-lowering therapy.

“The shift to a longer view of cardiovascular disease risk is a sea change for doctors in counseling patients,” said lead author Timothy Anderson, MD. He emphasized that treatment decisions for younger, lower-risk adults should account for potential benefit, adverse effects, cost, lifestyle options, and patient preferences.

Sources:

Anderson TS, Wilson LM, Sussman JB. (2026 July 20) JAMA. Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy

Peng AW, Zahid S, Zhang S, et al. (2026 July 20) JAMA. Cardiovascular Risk Reclassification With the 2026 Dyslipidemia Guideline

Abohashem S, Martin SS, Hassan I, et al. (2026 July 20) JAMA. Prevalence of LDL-C Above 2026 Dyslipidemia Guideline Goals Among US Adults

Greenland P, Lasser KE. (2026 July 20) JAMA. New Dyslipidemia Guidelines Lower the Lipid Treatment Goals and Raise the Bar for Clinical Practice